PROTEIN KINASE ANTAGONISTS: PRECLINICAL AND CLINICAL
PROTEIN KINASE ANTAGONISTS: PRECLINICAL AND CLINICAL
批准号:
6290796
负责人:
EDWARD A. SAUSVILLE
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
MCF7 cell antineoplastics apoptosis cell cycle cis platinum compound clinical research clinical trial phase I cyclin dependent kinase cyclins drug screening /evaluation enzyme inhibitors enzyme substrate flavones human subject low angle X ray diffraction analysis neoplasm /cancer chemotherapy neoplasm /cancer pharmacology neoplastic cell neoplastic growth oncoproteins pharmacokinetics phosphorylation radiosensitizer retinoblastoma protein
中文摘要
该项目区正在研究两种蛋白激酶拮抗剂,即黄烷醇和UCN-01,进行初步的I期临床试验。此外,在列出的项目期内,采用了通过包括Perifosine在内的烷基磷脂间接修饰蛋白激酶信号通路的方法。完成了UCN-01的I期试验,第一个疗程72小时持续输注,然后每4周减半剂量,并公布了初步结果(ASCO,1999)在初始试验中治疗了47名患者。剂量限制毒性包括肺部、高血糖和乳酸酸中毒。MTD为42.5 mg/m~2/d×3。其他毒性包括乏力、低血压和肌痛。初步研究表明,与在小鼠、大鼠和狗身上进行的临床前研究相比,UCN-01的人类药理学有显著不同。具体地说,人类对血浆α酸性糖蛋白有很高的亲和力,因此有很长的药物半衰期(T1/2和1000小时),并耐受更高浓度的药物。未来的计划是考虑未来阶段的输液持续时间更短,并与标准化疗药物联合使用。基于对血液系统肿瘤疗效的临床前研究,一项使用间歇性给药的I期试验已经展开。按Qd×5计划给药的初始MTD为37 mg/m~2/d。峰值浓度正在达到2微米以上。服药期间正在成功减少,Qd×3计划完成,预计2000财年每周计划一次。作为负荷量给药和每日持续口服给药的Perifosine的初始剂量水平似乎耐受性良好。在2000财年,还将制定头颈部鳞癌患者间歇性静脉推注黄烷醇的第二阶段方案。-细胞信号、化疗药物、药代动力学、药理学、蛋白激酶、-人体研究对象和人体组织、体液、细胞等。
英文摘要
This project area is studying in initial Phase I clinical trials two protein kinase antagonists, flavopiridol and UCN-01. In addition, indirect means of modifying protein kinase signalling pathways through alkylphospholipids including Perifosine was undertaken during the project period listed. A phase I trial of UCN-01 administered as a 72 hr continuous infusion for the first course, followed by half the dose every four weeks was completed, and preliminary results presented(ASCO, 1999) Forty-seven patients were treated on the intial trial. Dose limiting toxicities included pulmonary, hyperglycemia, and lactic acidosis. The MTD is 42.5 mg/M2/d x 3. Additional toxicities included fatigue, hypotension, and myalgias. Initial studies revealed a marked difference in the human pharmacology of UCN-01, in comparison to pre- clinial studies in mice, rats, and dogs. Specifically, humans have high affinity binding to plasma alpha acidic glycoprotein, and therefore have very long half times (T1/2 > 1000 hr) of the drug and tolerate much higher concentrations of drug. Future plans are to consider future Phase Is of more brief infusion duration and in combination with standard chemotherapy agents. A Phase I trial utilizing intermittent bolus dosing of flavopiridol, based on preclinical studies of efficiacy in hematopoietic neoplasms has been undertaken. The initial MTD when administered on a qd x 5 schedule was 37 mg/M2/d. Concentrations at peak in excess of 2 uM are being achieved.Successive decreases in the period of dosing are being undertaken, with completion of qd x 3 and once weekly schedules anticipated during FY2000. Initial dose levels of perifosine, administered as a loading dose and a continued daily oral dosing appear well tolerated. A Phase II protocol of intermittent IV bolus dosing of flavopiridol in patients with squamous carcinoma of the head and neck will be developed also in FY2000. - cell signaling, chemotherapeutics, pharmacokinetics, pharmacology, protein kinase, - Human Subjects & Human Tissues, Fluids, Cells, etc.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: TREATMENT OF MELANOMA WITH WILD-TYPE P53 AND A 100B USING PENTA
-
批准号:7951182
-
项目类别:
-
资助金额:$0.96万
-
财政年份:2009
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
-
批准号:8332885
-
项目类别:
-
资助金额:$106.57万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
-
批准号:7928077
-
项目类别:
-
资助金额:$112.12万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
-
批准号:7470184
-
项目类别:
-
资助金额:$29.5万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Treatment of Melanoma with wild-type P53 and detectable S100B using pentamidine:
-
批准号:7529101
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Clinical Research Shared Service
-
批准号:7696610
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
-
批准号:8141280
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Treatment of Melanoma with wild-type P53 and detectable S100B using pentamidine:
-
批准号:7642487
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
-
批准号:8548092
-
项目类别:
-
资助金额:$82.69万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
UMGCC Paul Calabresi Clinical Oncology Training Program
-
批准号:7683191
-
项目类别:
-
资助金额:$70.81万
-
财政年份:2008
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
0629GCC: A PHASE I, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY TO ASSESS SL
-
批准号:7608176
-
项目类别:
-
资助金额:$0.32万
-
财政年份:2007
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
0458GCC: A PHASE I DOSE ESCALATION STUDY OF INTRAVENOUS 17-AAG
-
批准号:7608152
-
项目类别:
-
资助金额:$4.07万
-
财政年份:2007
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
PHASE 1 OF SORAFENIB PLUS 17AAG IN SOLID TUMOR PATIENTS
-
批准号:7376971
-
项目类别:
-
资助金额:$2.03万
-
财政年份:2006
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Protein Kinase Antagonists: Preclinical and Clinical
-
批准号:6558398
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Protein Kinase Antagonists: Preclinical and Clinical
-
批准号:6433383
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Clinical Protocol and Data Management
-
批准号:9145406
-
项目类别:
-
资助金额:$12.55万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Immunotoxin Protocols Under the Medicine Branch: Targeted Therapy of Lymphoid Ne
-
批准号:6433124
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Immunotoxin Protocols Under the Medicine Branch: Targete
-
批准号:6558377
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
Early Phase Clinical Research Support
-
批准号:9326171
-
项目类别:
-
资助金额:$13.91万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
IMMUNOTOXIN PROTOCOLS UNDER THE MEDICINE BRANCH: TARGETED THERAPY OF LYMPHOID NEO
-
批准号:6290777
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:EDWARD A. SAUSVILLE
-
依托单位:
海外基金